market assesment: great new product or just really cool science?
DESCRIPTION
Part of the MaRS BioEntrepreneurship series Speaker: Kelly Holman Managing Director , Genesys Capital Partners Inc * Realistically assess commercial readiness of the technology * Forecast and value addressable market opportunity for your technology * Understand how financiers evaluate early stage biotech opportunities To download the audio presentation: http://www.marsdd.com/bioent/nov13 For the event blog summary and Q+A: http://blog.marsdd.com/2006/11/14/bioentrepreneurship-market-assessment-great-new-product-or-just-really-cool-science/TRANSCRIPT
![Page 1: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/1.jpg)
Market Assessment:Great new product or just really cool science?
MaRS BioEntrepreneurship Events SeriesNovember 13, 2006
![Page 2: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/2.jpg)
In the beginning…
At some stage
all great new products
were
“just really cool science”
![Page 3: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/3.jpg)
Learning Objectives
● Commercialization considerations
● Assessment of the commercial path fortechnology/product
● Market assessment for technology/product
● VC considerations of early-stage lifesciences opportunities
![Page 4: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/4.jpg)
In the beginning…
At some stage
all great new products
were
“just really cool science”
The first wave of biotech companies (e.g.Amgen, Biogen, Genentech) were born of theCohen/Boyer recombinant DNA technology
![Page 5: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/5.jpg)
So…
Q: …how does one carry out an assessment todetermine if your “really cool science” hascommercial potential?
A: …unfortunately there is no formula
![Page 6: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/6.jpg)
You are an entrepreneur or you are not…
● Going down the path to commercializingyour technology is determined more by yourstate of mind than decision tree analysis
![Page 7: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/7.jpg)
You are an entrepreneur or you are not…
● However, if and/or when you do go downthe path, there are:
— some considerations— tools to be applied
![Page 8: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/8.jpg)
Considerations
![Page 9: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/9.jpg)
Considerations
● What do you give up by going down acommercial path?
— Examples:• Academic freedom• Ability to publish freely• Curiosity-driven research/activity• Different standard of accountability (commercial
endpoints vs. scientific advancement)• Job security
![Page 10: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/10.jpg)
Considerations
● What do you gain by going down acommercial path?
— Examples:• Potential to see science applied• Potential for significant financial gain• Likely faster pace• Potential for significant financial support• Less threat of political volatility (e.g. grant funding)
![Page 11: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/11.jpg)
Considerations
● If you do go down a commercial path you need toacquire a thorough understanding of what it is youare trying to accomplish
● Some relevant questions:— What product are you trying to develop?— How unique is it? Protectable? Class-leading/peer-leading
science?— What is the market need?— How big is the market opportunity?— What needs to be accomplished to move it from where it
is today to market?— How much capital is required and where will that come
from?— Where will I get help?
![Page 12: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/12.jpg)
You are an entrepreneur or you are not…
Ask yourself these questions – and if you don’tget excited about finding the answers thenyou have the answer…
![Page 13: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/13.jpg)
Considerations
● What product are you developing?— This will hinge on your science and its potential— Have you:
• discovered a novel pathway related to [fill in theblank disease condition]?
• observed an unknown therapeutic effect that can betreated with an existing agent?
• discovered a novel molecule (protein, antibody,chemical) that could have a therapeutic effect?
• Etc.
![Page 14: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/14.jpg)
Considerations
● How unique is it?— Is it class-leading science?— Is it peer-leading science?— Is it patentable? – novel? useful? non-obvious?— Is it protectable?— Do you/will you have freedom-to-operate?
![Page 15: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/15.jpg)
Considerations
Some inventions/technology are closer toproduct than others
However none are products yet! (let alone“great new products”)
Not until a health regulator (FDA, HealthCanada, etc) agrees
![Page 16: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/16.jpg)
Considerations
How do I get there from here?
![Page 17: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/17.jpg)
Drug Discovery and Development Process
![Page 18: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/18.jpg)
Path to Commercialization
![Page 19: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/19.jpg)
Path to Commercialization
Where are you in the process?
![Page 20: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/20.jpg)
Where are you in the process?
![Page 21: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/21.jpg)
How much data do I need?
● How many NOD/SCID mice?
● Knock-ins? Knock-outs?
● Results in relevant animal models?● How many compounds in your lead series?
● What are the MICs?
● Tested in how many different animal species?● How many steps involved in chemical synthesis?
● Scalable? Estimated manufacturing costs?● Long term toxicology results - 10 days? 28 days?
● No effect dose (NOAEL)?
● MTD?● Therapeutic window?
● IND filing?
● How many patients?● Long-term human efficacy data?
● NDA filing?
![Page 22: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/22.jpg)
How much data do I need?
Someone will always want to see more…
![Page 23: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/23.jpg)
Commercialization Risks
● Manufacturing
● Partnering
● Reimbursement
● Regulatory
● Market● Human Resources/Management
● Financing
● Intellectual Property
● Scientific/Technical/Clinical Development
![Page 24: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/24.jpg)
Estimating your Costs
● The product’s pre-clinical/clinicaldevelopment costs will far exceed yourdiscovery costs
● Breakdown your costs:— Key discovery costs— Key pre-clinical costs— Key clinical costs
● Seek third party costing inputs soonerrather than later
![Page 25: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/25.jpg)
Estimating your Costs
● Key Discovery costs (net of HR/personnel)— Lab space/equipment— Biology (e.g. animals)— Chemistry— Patent filings
● Key pre-clinical costs (net of HR/personnel)— Drug substance (formulation, stability)— In vitro testing— Animal toxicity— Animal efficacy— Outsourced expertise (e.g. clin, reg)— Patent filings
● Key Clinical Costs (net of HR/personnel)— =f(# of patients, # of sites, time to endpoint)— Drug substance— Patent filings, patent maintenance
![Page 26: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/26.jpg)
Market Assessment
![Page 27: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/27.jpg)
Key Challenge: Predicting the Future
![Page 28: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/28.jpg)
Market Opportunity
● What disease area are you targeting?
● What is the prevalence of disease?
● What is the incidence of disease?
● What is the projected growth in incidence?
● What are the current state-of-the-arttreatments?
● Who pays for it and how much?
![Page 29: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/29.jpg)
Market Opportunity
● Market segmentation— Type of disease— Acute/chronic— Stage of disease— First-line, second-line, etc.— Hospital/community product— Delivery method (oral, IV, inhalable, injectable,
etc)— Geography— Etc.
![Page 30: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/30.jpg)
Market Opportunity
Competitive Landscape1. Marketed products2. Products in development3. New scientific advancements
What are the technology/product differentiators?— (e.g. efficacy, tox profile, dosing schedule, delivery
method, cost, etc)
● This market analysis becomes more relevant thecloser you are to the market
![Page 31: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/31.jpg)
Market Assessment
![Page 32: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/32.jpg)
Where to find industry numbers
● Examples:— Market Research Publications (Decision Resources, F&S,
etc)— Niche Professional Market Research Analysts (e.g.
contracted clinical/scientific focus group work)— IMS— Windhover, Scrip, ReCap, BioCentury, Bioworld,— Industry and scientific/clinical network (e.g. “thought-
leaders”)— Investment Banking analyst reports— SEC disclosures— Corporate Presentations— Tradeshows— CMS (e.g. Medicare, Medicaid reimbursement numbers)
![Page 33: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/33.jpg)
Key Challenge: Predicting the Future
Catch-22: you need to make the decisionto commercialize before you have themarket data to make a well-informeddecision about whether you should
commercialize
![Page 34: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/34.jpg)
You are an entrepreneur or you are not…
● Going down the path to commercializingyour technology is determined more by yourstate of mind than decision tree analysis
![Page 35: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/35.jpg)
VC Considerations
![Page 36: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/36.jpg)
VC Considerations
● Objective of VC: To generate superior financialreturns across a portfolio of companies
— ~10% net annualized return over public market proxies
● Each investment opportunity should have thepotential for 5+ X return over 3 to 7 years
● VCs are searching for the “New New” thing (i.e.typically undefined territory) to invest in
— High Risk— Pre-product— Pre-revenue
![Page 37: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/37.jpg)
VC Considerations
● In order to evaluate/assess an investmentopportunity – conduct comprehensive due diligence
● Due Diligence should help identify investment risks
● Due Diligence should aid in answering the followingquestions:
— Should we invest - Yes/No? If Yes, on what terms? (structure,amount, valuation, plan and use of proceeds)
● Invest the resources (time/money) in accessing thebest sources of information and perspectives
● Ongoing process – post-investment monitoring
![Page 38: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/38.jpg)
VC Considerations
● Areas of Focus for Due Diligence:— Technical/scientific— Clinical plans/Development path— Intellectual Property – Patentability and FtO— Market Opportunity— People/Management— Financing Needs/Plans— Business Model
![Page 39: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/39.jpg)
VC Challenges
● Making investment decisions with imperfectinformation
— In any early-stage opportunity there are a number ofunknowns – technology, IP, market, people, etc
● The earlier the investment, the less perfect theinformation
— Higher risk, higher return expectation
![Page 40: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/40.jpg)
The Art & Science of Valuation
![Page 41: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/41.jpg)
“Most valuation exerciseswind up being attempts
to defend intuitive decisionsby placing them
in a quantitative framework”
Stelios Papadopoulos, PhD. Managing Director, SG Cowen
Valuation exercises…
![Page 42: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/42.jpg)
Valuation is…
● a forecast of the future value of operating profitsand cash flows
● influenced by many factors— Company, Industry, Macroeconomic
● a function of perspective (buyer/seller)
● , in the context of a completed transaction, anegotiated price between the buyer and the seller
![Page 43: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/43.jpg)
Value Drivers
● Management— Experience, track record, market awareness
● Technology— Uniqueness, strength of IP portfolio, scientific expertise
● Market Opportunity— Need, size, growth rate, competitive position
● Revenue Model— Profit Margins
● Partnerships and Alliances— Venture Investors, Commercial partners
● Stage of Development
![Page 44: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/44.jpg)
Valuation as Art
● Quality of the Management— Track record, experience, market awareness
● Quality of Technology and Scientific team
● Quality of Sponsorship— Venture Investors, Commercial partners
![Page 45: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/45.jpg)
Valuation as Science
Several different quantitative methods to derive avaluation:
1. Discounted Cash Flow2. Comparable Market Data3. Option Pricing Model
Challenges :— Generating a financial model— Accounting for the high level of risk— Venture Capital investors have a high hurdle rate (40+%)
![Page 46: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/46.jpg)
Valuation – NPV relevance
![Page 47: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/47.jpg)
1. Discounted Cash Flow
● Method of converting future cash flow into theirpresent equivalents taking into account:— the timing of the cash flows— the risk associated with the cash flows
● Apply discount rates (to reflect risk plus inflation)— Rule-of-thumb discount rates range from 80+% for Discovery
stage to 10-15% for Market stage
![Page 48: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/48.jpg)
2. Comparable Market Data
● Develop a database of transaction prices andcurrent prices to use as a reference to derive arelative valuation
● Sources for database:— Private company valuations— Public company valuations— Acquisition valuations
![Page 49: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/49.jpg)
3. Option Pricing
● Use a model to value alternatives andopportunities related to a product/technology
— Estimate cash flow for each alternative and opportunity— Apply probabilities to a collection of options, at various
points in time
![Page 50: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/50.jpg)
Factors affecting valuation
● Regulatory issues— Product development: very risky, expensive and
lengthy process
● Cyclical financing environments— As industry matures, cycles should be less volatile
● Esoteric science— Difficult to communicate the value and to
differentiate stories
● In Canada, management and local private/publicequity market (supply/demand) challenges
![Page 51: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/51.jpg)
Picking a Financial Partner (Angel, VC, Corporate)
● Think long-term
● Do your homework (due diligence)
● Interests should be aligned— Growth, management, exit
● “More than money”— Expertise, strategy, recruiting, governance— Highest price may not be from preferred partner/investor – see first
point above
● In good times and in bad— Future funding, patient capital
● Track record of success
● Personal dynamics
![Page 52: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/52.jpg)
Valuation Summary
● Valuation is subjective – price is a negotiatednumber
● Exercise is part art, part science
● Methods provide framework in which to:— assess investment opportunities— gauge sensitivities— Intersecting ranges derived from various methodologies
should increase confidence in the valuation
● VCs have a high hurdle rate
![Page 53: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/53.jpg)
Summary
![Page 54: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/54.jpg)
Drug Discovery and Development Process
![Page 55: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/55.jpg)
Summary
● At some stage all great new products were “reallycool science”
● Being an entrepreneur is a state of mind
● Commercialization process is well-defined(influenced by precedents)
● Predicting the future is difficult— Market assessment exercises become more relevant the
closer the product is to the market— Remember the “Catch-22”
● VCs need their financial reward to becommensurate with the risk
![Page 56: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/56.jpg)
Q&A
![Page 57: Market Assesment: Great New Product or Just Really Cool Science?](https://reader034.vdocuments.site/reader034/viewer/2022051412/54b501804a795945748b479b/html5/thumbnails/57.jpg)
Market Assessment:Great new product or just really cool science?
MaRS Events Series November 13, 2006